  employees of the Group. The long -term incentive program 2021 includes 
two elements: one performance -based share rights program, and o ne employee stock option program. 
The CEO has been granted 80,000 share rights and 120,000 employee stock options (“ESO”) under 
the long -term incentive program 2021. 
Under the performance -based share rights program, each share right entitles the holder to receive one 
ordinary share in Hansa Biopharma AB free -of-charge provided that the below performance conditions 
are met during the vesting period. In addition to the r equirement for the participant’s continued 
employment, the final number of shares that each participant is entitled to receive is also conditional 
upon the following performance conditions being met during the vesting period: (a) 22 percent of the 
shares i n the event that at least 56 patients were randomized in the US ConfIdeS study , (b) 11 percent 
of the shares in the event that the GBS phase 3 development strategy align al Report 2024Overview Strategy Growth Shareholder 
informationDirectors’ 
reportFinancials Governance Remuneration Glossary

5 Remuneration report 2024 continued Remuneration of the CEO in share rights and employee stock options 
Table 2 – Remuneration of the CEO in share rights 
Name, position The main conditions of share rights Information regarding the reported financial year Opening balance During the year 202 4 Closing balance 31 Dec 202 4 
1 Name of plan 2 
Performance period 3 Award date 4 Vesting date 5 
End of retention period 6 Share rights held 
 at the beginning of the year 7 Awarded 8 Vested 9 Expired 10 Subject to a 
performance condition(s) 11 
Awarded and unvested 12 
Rights subject to a retention period Søren Tulstrup 
(CEO) LTIP2021 2021 -2024 2021 -06-07 2024 -06-07 2024 -06-07 80,000 0 35,200 44,800 0 0 0 LTIP2022 2022-2025 2022-07-20 2025-07-20 2025-07-20 80,000 0 0 0 80,000 80,000 80,000 LTIP2023 2023 -2026 2023 -11-06 2026 -11-06 2026 -11-06 100,000 0 0 0 100,00  share rights program under the LTIP 202 1, in which the CEO held 80,000 performance share rights, hit the vesting date. Since the pre -defined performance criteria were only partly met, plan 
participants received 44% of the maximum potential share allocations. The CEO received 35,200 shares. Further, in 202 4, the employee stock option (“ESO”) program under the LTIP 202 1, in which the CEO 
holds 12 0,000 ESOs, vested. In accordance with the terms of the LTIP 202 1, plan participants may exercise the vested ESOs over a 3 -year period from vesting through 6 July 202 7 at an exercise price of SEK 
192.20. 
Set out in Table 4 below is a description of how the criteria for payment of variable short -term compensation have been applied for the financial year 202 4. Such criteria are based on the annual corporate 
objectives and form the basis for the short -term performance measurement of the CEO and, together with pre -defined individual objectives, accounting for up to 80% of the perfor to 80% of the performance targets for all other 
members of the executive management. 
Table 4 – Criteria for payment of variable short -term compensation Name, Position Description of the criteria related to the corporate goals 2024 corporate goals Overall weight a) Measured goal achievement and b) Actual weighted outcome Søren Tulstrup, CEO Imlifidase commercial launch – Sales, market access, EMA post-approval commitments 2 sub-goals 20% a) 80% b) 17% Progressing pipeline activities in transplantation, autoimmune indications, gene therapy and HNSA-5487 6 sub-goals 45% a) 100% b) 45% Business development and financial strength 2 sub-goals 30% a) 50% b) 15% Corporate Social Responsibility 1 sub-goal 5% a) 100% b) 5% Total: 82% 
 
Comparative information on remuneration and Company performance 2024 2023 CEO remuneration Søren Tulstrup, CEO SEK 14,101k SEK 13,369k 
Company’s performance 
 Achievement of the annual corporate objectives 82% 85% 
 Operating profit / (loss) SEK ( 637,878k) S